FIELD: genetic engineering.
SUBSTANCE: isolated mRNA sequence for the expression of one or more polypeptides in one or more target organs, containing at least one coding sequence that encodes at least one polypeptide, at least the first untranslated region (UTR) sequence, and a plurality of microRNA binding site sequences (miRNA) is described. Each of the miRNA binding site sequences is located within the first UTR sequence directly adjacent to it from the 5'-end, or directly adjacent to it from the 3'-end; and miRNA binding site sequences provide for differential expression of the coding sequence in at least the first and second cell types in the target organ or organs.
EFFECT: creating a composition for improved targeted cytokine therapy with flexible protection against off-target effects.
19 cl, 28 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT ONCOLYTIC VIRUS, METHOD FOR ITS PRODUCTION, ITS APPLICATION AND THE DRUG ON ITS BASIS | 2020 |
|
RU2795230C1 |
| ONCOLYTIC VIRAL VECTORS AND THEIR APPLICATION | 2018 |
|
RU2771110C2 |
| DESIGNING OF CARCINOLYTIC ADENOVIRUS RECOMBINANT, SPECIFICALLY EXPRESSING IMMUNOMODULATORY FACTOR GM-CSF IN TUMORAL CELLS AND ITS APPLICATION | 2004 |
|
RU2361611C2 |
| POLYNUCLEOTIDES CODING INTERLEUKIN-12 (IL12), AND APPLICATIONS THEREOF | 2017 |
|
RU2769316C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| METHOD FOR INCREASING RNA EXPRESSION IN CELL | 2018 |
|
RU2784654C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| METHOD OF T-CELL ACTIVATION/PROLIFERATION | 2019 |
|
RU2806549C2 |
| NON-TOXIC VECTORS ON HSV BASIS FOR APPLICATIONS IN EFFECTIVE GENE DELIVERY AND COMPLEMENTING CELLS FOR THEIR PRODUCTION | 2014 |
|
RU2714259C2 |
